Elutia Inc. (ELUT)
| Market Cap | 36.02M -6.6% |
| Revenue (ttm) | 12.14M -0.3% |
| Net Income | 51.81M |
| EPS | 1.01 |
| Shares Out | 44.29M |
| PE Ratio | 0.81 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 37,677 |
| Open | 0.8200 |
| Previous Close | 0.8210 |
| Day's Range | 0.8113 - 0.8599 |
| 52-Week Range | 0.5000 - 1.3850 |
| Beta | 0.84 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About ELUT
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac pat... [Read more]
Financial Performance
Financial StatementsNews
Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
GAITHERSBURG, Md., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its ...
Elutia receives $8M payment from Boston Scientific
Elutia (ELUT) has received the full $8M held in escrow in connection with the sale of its BioEnvelope business to Boston Scientific (BSX). The payment was made following an indemnity…
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
Boston Scientific released the full $8 million holdback on schedule and with no claims Escrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its A...
Elutia Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A drug-eluting biomatrix platform aims to reduce high infection rates in breast reconstruction, with strong surgeon demand and a $1.5 billion market opportunity. Regulatory clearance is expected by 2027, with commercialization fully funded and expansion into additional surgical markets planned.
Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th
GAITHERSBURG, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Ch...
Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference
GAITHERSBURG, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Ch...
Cellution Biologics completes SimpliDerm acquisition from Elutia
Cellution Biologics announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix business from Elutia (ELUT). The acquisition marks Cellution Biologics’ entry i...
Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.
ROSWELL, Ga., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Cellution Biologics Inc. (“Cellution Biologics” or the “Company”), a biologics company focused on developing, manufacturing and commercializing advanced...
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch
Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 months Divestiture further concentrates Elutia's attention and res...
Elutia Earnings Call Transcript: Q2 2026
Q2 saw focused execution with divestitures and $26M in new funding, supporting NXT-41x development and launch. Gross margin improved to 70.7% (adjusted), net loss narrowed, and surgeon demand for NXT-41x is strong. Regulatory and manufacturing milestones remain on track.
Elutia Earnings release: Q2 2026
Elutia released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Elutia Slides: Q2 2026
Elutia has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
Elutia Quarterly report: Q2 2026
Elutia has published its Q2 2026 quarterly earnings report on August 13, 2026.
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results
Funded through launch: secured up to $26 million of capital without an equity offering The unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection risk The dema...
Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market
$10 million funded at closing; second $5 million tranche unlocked upon FDA 510(k) clearance of NXT-41x Preserves shareholder value by funding commercialization of Elutia's next-generation antibiotic-e...
Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
GAITHERSBURG, Md., July 31, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its ...
Elutia to sell SimpliDerm business to Cellution Biologics for $11M
Elutia (ELUT) announced the signing of a definitive agreement to sell its SimpliDerm human acellular dermal matrix business to Cellution Biologics for total consideration of up to $11M. Elutia will…
Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch
Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch
Elutia Transcript: Planet MicroCap Las Vegas 2026
A drug-eluting biologic platform is being advanced for breast reconstruction, addressing a $1.5 billion U.S. market with high infection rates. The product delivers local antibiotics via mesh, with regulatory approval expected next year and a focused commercialization plan targeting top centers.
Elutia to Present at Planet MicroCap Showcase 2026 on June 17th
GAITHERSBURG, Md., June 11, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chi...
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity awa...
Elutia Transcript: 16th Annual LD Micro Invitational Conference
A proven antibiotic-eluting matrix platform is being adapted for breast reconstruction, targeting a $1.5 billion U.S. market with high infection rates. FDA approvals are expected within a year, with a cost-neutral, high-margin commercialization strategy focused on top hospitals.
Elutia Earnings Call Transcript: Q1 2026
Q1 2026 saw 6% revenue growth, improved gross margins, and strong liquidity. Regulatory progress and manufacturing advances support confidence in NXT-41x, with FDA clearance and commercialization targeted for 2026–2027. Strategic divestitures are underway.
Elutia Earnings release: Q1 2026
Elutia released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Elutia Slides: Q1 2026
Elutia has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 14, 2026.